The incidences of PD-1 inhibitor and ipilimumab induced grade 3–4 hepatitis were 1.8% and 2.6%, respectively, which is comparable to previously published incidences [3, 4, 7, 8]. This evidence concerns the gene PDCD1 and hepatitis A virus infection.